VGXI Welcomes Michael Stewart as New Chief Operating Officer
CONROE, Texas, March 4, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, proudly announces the appointment of Michael Stewart as its new Chief Operating Officer (COO).
- CONROE, Texas, March 4, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, proudly announces the appointment of Michael Stewart as its new Chief Operating Officer (COO).
- Stewart brings over 20 years of extensive experience in the viral vector therapy and vaccine production industry, which will be instrumental to VGXI's continued growth and success.
- "We are thrilled to welcome Michael Stewart to VGXI as our new Chief Operating Officer," said VGXI's CEO, Young Park.
- Please join VGXI in extending a warm welcome to Michael Stewart as he assumes his new role as Chief Operating Officer, effective immediately.